Kezar Life Sciences
About: Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Employees: 58
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
34% more capital invested
Capital invested by funds: $23.6M [Q2] → $31.6M (+$8.02M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0.52% less ownership
Funds ownership: 54.11% [Q2] → 53.59% (-0.52%) [Q3]
26% less funds holding
Funds holding: 81 [Q2] → 60 (-21) [Q3]
39% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 23
81% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 26
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
32%
upside
Avg. target
$9
32%
upside
High target
$9
32%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Wells Fargo Derek Archila 50% 1-year accuracy 18 / 36 met price target | 32%upside $9 | Equal-Weight Maintained | 19 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
1 month ago
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,”.
Neutral
Business Wire
1 month ago
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possible violations of state laws. If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY.
Neutral
Business Wire
1 month ago
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the “Effective Time”). The Co.
Neutral
Business Wire
2 months ago
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the “Board”) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o.
Neutral
Business Wire
2 months ago
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key clinical development updates. The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH recommended that the trial may proceed without modification following its third scheduled meeting. The IDMC examined safety data from a.
Positive
Zacks Investment Research
2 months ago
What Makes Kezar Life Sciences (KZR) a New Buy Stock
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
2 months ago
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”), a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per s.
Negative
Reuters
2 months ago
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial
The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.
Neutral
Business Wire
2 months ago
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN) has been placed on clinical hold. This action follows Kezar's communication t.
Negative
Reuters
2 months ago
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths.
Charts implemented using Lightweight Charts™